LT

Lithuania

Medical Only (Private)

Reimbursed Care Access

Most classical psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, mescaline, 2C‑X, ayahuasca) are controlled and not authorised for medical use in Lithuania outside of approved research. Ketamine is an established medical anaesthetic used in hospitals and is used off‑label in private clinics for depression; esketamine (Spravato) is registered in Lithuania but routine public reimbursement appears limited and treatment is typically delivered under specialist supervision or via private providers/clinics.

Quick Indicators

Active Trials

0

Total Trials

4

Organizations

0

Events

0

Reimbursement Guide→All Countries→Clinical Trials→Research Papers→

Clinical Trials

Active and completed clinical trials investigating psychedelic-assisted therapies in Lithuania.

CompletedPhase III

A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (ASPIRE II)

Started: June 15, 2017

CompletedPhase III

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Started: June 9, 2016

CompletedPhase III

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression (SUSTAIN-2)

Started: September 30, 2015

CompletedPhase III

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression (TRANSFORM-3)

Started: August 20, 2015